Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DNA
SellSinkerGinkgo Bioworks Holdings, Inc. · Healthcare · United States · $469M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Ginkgo Bioworks Holdings, Inc. operates a horizontal platform for cell programming, providing research and development services to customers across agriculture, pharmaceuticals, and industrial chemicals. The company leverages its proprietary 'Foundry' and 'Codebase' to reduce the cost and time of biological design, benefiting from scale economies as more programs are added. It is a leading, platform-based synthetic biology pioneer.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.7M | 251.5M | 227.0M | 170.2M | -29.1% | 132.4M | 85.0M | 96.4M | -24.7% |
| EPS | -50.00 | -18.37 | -10.54 | -5.64 | — | -5.33 | -3.20 | -2.90 | — |
| Shares | 47.3M | 50.0M | 54.4M | 58.2M | +23.1% | 55.4M | — | — | — |
| Debt | 442.6M | 239.3M | 467.7M | 439.9M | -0.2% | 404.1M | — | — | — |
| Equity | 1.7B | 1.1B | 716.1M | 508.6M | -33.6% | — | — | — | — |
| Op CF | -252.2M | -295.5M | -319.6M | -171.1M | — | -170.2M | — | — | — |
| Inv CF | -67.4M | -80.7M | -62.2M | -240.3M | — | — | — | — | — |
| Fin CF | 95.3M | -3.2M | -1.7M | 17.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DNA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc.(you) | $469M | 21 | Sell |
| RLMD | Relmada Therapeutics, Inc. | $462M | 20 | Sell |
| RZLT | Rezolute, Inc. | $445M | 21 | Sell |
| BNTC | Benitec Biopharma Inc. | $428M | 23 | Sell |
| MPLT | MapLight Therapeutics, Inc. | $584M | 22 | Sell |
| CCCC | C4 Therapeutics, Inc. | $474M | 26 | Sell |
| ARCT | Arcturus Therapeutics Holdings Inc. | $432M | 25 | Sell |
| ZURA | Zura Bio Limited | $548M | 19 | Strong Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
| XFOR | X4 Pharmaceuticals, Inc. | $401M | 25 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%